CCL2 and posterior cortical atrophy: However, 4.5% (1,142/25,356) of the total cohort also had additional biomarkers (EGF, MCP-1, IL-8) measured with tPSA, to assess PCa risk as part of their Randox Health check (biomarker cohort, n = 1,142).